Edition:
United States

Merus NV (MRUS.OQ)

MRUS.OQ on NASDAQ Stock Exchange Global Market

14.74USD
15 Dec 2017
Change (% chg)

$0.39 (+2.72%)
Prev Close
$14.35
Open
$14.94
Day's High
$14.94
Day's Low
$14.44
Volume
2,522
Avg. Vol
5,917
52-wk High
$33.48
52-wk Low
$13.33

Latest Key Developments (Source: Significant Developments)

Merus Nv Q3 Loss Per Share Eur 0.81
Thursday, 30 Nov 2017 07:00am EST 

Merus Nv ::MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS.Q3 LOSS PER SHARE EUR 0.81.Q3 REVENUE EUR 3.5 MILLION VERSUS EUR 1.2 MILLION.Q3 REVENUE VIEW EUR 2.2 MILLION -- THOMSON REUTERS I/B/E/S.Q3 EARNINGS PER SHARE VIEW EUR -0.58 -- THOMSON REUTERS I/B/E/S.- ‍EXPECTS CURRENT CASH AND CASH EQUIVALENTS BALANCE TO BE SUFFICIENT TO FUND RESEARCH AND DEVELOPMENT PROGRAMS AND OPERATIONS WELL INTO 2019​.  Full Article

Merus announces Q2 loss per share EUR 1.12
Tuesday, 19 Sep 2017 04:05pm EDT 

Sept 19 (Reuters) - Merus NV :Merus announces second quarter 2017 financial results and highlights recent progress.Q2 loss per share EUR 1.12.Q2 revenue EUR 4.0 million versus EUR 1.1 million.Q2 revenue view eur 2.2 million -- Thomson Reuters I/B/E/S.Q2 earnings per share view EUR -0.52 -- Thomson Reuters I/B/E/S.Merus NV - Expects that current cash and cash equivalents balance will be sufficient to fund research and development programs, operations well into 2019.  Full Article

Merus Q1 loss per share EUR 1.15
Tuesday, 11 Jul 2017 04:05pm EDT 

July 11 (Reuters) - Merus Nv ::Merus announces first quarter 2017 financial results and mid-year operating results.Q1 loss per share EUR 1.15.Q1 revenue EUR 2.3 million versus EUR 800,000.Q1 revenue view EUR 42.8 million -- Thomson Reuters I/B/E/S.Q1 earnings per share view EUR 1.55 -- Thomson Reuters I/B/E/S.Merus nv says by end of 2017, Merus expects to file a CTA for a first-in-human clinical trial of mcla-158 in patients with colorectal cancer.  Full Article

Merus reports Q4 loss per share eur 1.91
Friday, 28 Apr 2017 04:48pm EDT 

April 28 (Reuters) - Merus Nv -:Merus announces fourth quarter and full year 2016 financial results and corporate developments.Q4 loss per share eur 1.91.Q4 revenue eur 1.1 million versus eur 400,000.Q4 earnings per share view eur -0.52 -- Thomson Reuters I/B/E/S.Q4 revenue view eur 701090.00 -- Thomson Reuters I/B/E/S.  Full Article

Johnson & Johnson reports 7.4 pct stake in Merus NV as of Dec 31, 2016
Wednesday, 18 Jan 2017 05:59pm EST 

Johnson & Johnson :Johnson & Johnson reports 7.4 percent passive stake in Merus NV as of Dec 31, 2016 - SEC filing.  Full Article

Incyte and Merus announce global strategic research collaboration
Wednesday, 21 Dec 2016 07:00am EST 

Incyte Corp : Incyte and Merus announce global strategic research collaboration to discover and develop bispecific antibodies . Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares . Merus eligible to receive potential development, regulatory and commercial milestones and sales royalties . Parties have agreed to collaborate on development and commercialization of up to 11 bispecific antibody programs . Merus will retain all rights to develop and commercialize approved products in united states . Merus also has option to co-fund development of product candidates arising from two other programs . Incyte - for eight programs merus to be eligible to get potential development, regulatory and sales milestone payments of up to $350 million per program . Incyte will develop and commercialize approved products arising from program outside united states . For eight programs Incyte has agreed to independently fund all development and commercialization activities .Merus also eligible to receive tiered royalties ranging from 6 to 10 percent on global sales of approved products under 8 programs.  Full Article

Merus NV Q2 loss per share EUR 0.40
Monday, 8 Aug 2016 07:00am EDT 

Merus Nv : Q2 loss per share eur 0.40 . Q2 earnings per share view eur -0.49 -- Thomson Reuters I/B/E/S . Merus announces second quarter 2016 financial results and reviews recent clinical progress and corporate developments .Q2 revenue eur 1.1 million versus eur 1.2 million.  Full Article

Merus announces Q1 loss per share EUR 0.63
Tuesday, 12 Jul 2016 07:00am EDT 

Merus NV : Merus announces first quarter 2016 financial results and highlights recent clinical progress and corporate developments . Q1 loss per share EUR 0.63 .Q1 revenue eur 800,000 versus EUR 100,000.  Full Article

Pfizer says takes 7.1 pct passive stake in Merus NV
Monday, 6 Jun 2016 05:39pm EDT 

Pfizer:Pfizer Says Takes 7.1 Pct Passive Stake In Merus NV Sec filing.  Full Article

Novartis reports 13.6 pct passive stake in Merus NV as of May 24, 2016
Friday, 3 Jun 2016 08:02am EDT 

Novartis AG :Reports 13.6 pct passive stake in Merus NV as of May 24, 2016 SEC fiilng.  Full Article

BRIEF-Merus Nv Q3 Loss Per Share Eur 0.81

* MERUS ANNOUNCES THIRD QUARTER 2017 FINANCIAL RESULTS AND CLINICAL HIGHLIGHTS